CAMBRIDGE, Mass., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 ...
Last week, Magenta Therapeutics announced plans to close down. This week, executive leadership and staff are being handed their pink slips. The stem cell transplant biotech is cutting 56 positions, or ...
Magenta Therapeutics Inc (NASDAQ: MGTA) and privately-held Dianthus Therapeutics Inc have announced to merge in an all-stock transaction. The combined company will focus on advancing Dianthus' ...
Magenta Therapeutics has been asked by the FDA to pump the brakes on a trial for its blood cancer med before it even got started. The FDA would like the biotech to develop an additional test to inform ...
Seemingly every brand offers some kind of loyalty program, but only a handful are really worth it. T-Mobile’s Magenta Status is one of them. Magenta Status is a free loyalty program for all postpaid T ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to more ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics, Inc. (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of stem cell transplant to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results